Table 6

Subgroup and sensitivity analyses

TB events in non-exposure group, (n)TB events in ICI exposure group, (n)HR (95% CI)P value
Subgroup analyses*
  <503710.62 (0.09 to 4.55)0.64
  ≥50859190.69 (0.44 to 1.09)0.11
  Male676160.71 (0.43 to 1.16)0.17
  Female22040.89 (0.33 to 2.42)0.83
 Cancer subtype0.98†
  NSCLC752190.76 (0.48 to 1.19)0.23
  Urothelial carcinoma13500.93 (0.06 to 15.15)0.96
  Melanoma910.84 (0.14 to 5.15)0.85
Sensitivity analyses*
 Defining TB by ICD-10 codes only1765440.83 (0.61 to 1.12)0.21
 Excluding TB cases within 30days following cancer diagnosis637150.89 (0.53 to 1.50)0.67
  • *All subgroup and sensitivity analyses were adjusted for age, sex, health insurance type, type of cancer, diabetes, hypertension, chronic lung disease, chronic kidney disease, chronic liver disease, rheumatic disease, active chemotherapy, concomitant immunosuppressant use, concomitant use of corticosteroid, and history of treatment for latent TB infection.

  • †P value for interaction.

  • ICD-10, International Classification of Diseases code version 10; ICI, immune checkpoint inhibitor; ; NSCLC, non-small cell lung cancer; PS, propensity matching; TB, tuberculosis.